Anal Dysplasia
11
2
3
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
18.2%
2 terminated out of 11 trials
60.0%
-26.6% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (11)
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
PDT Plus Vitamin D3 for Anal Dysplasia
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Application of Oral Bacteriotherapy to Promote Anal HPV Clearance in HIV Positive Individuals
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Screening for HIV-Associated Anal Cancer
Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia